Health equity and the usage of atypical antipsychotics within the Brazilian national health system: findings and implications

References

• Marmot M, Allen JJ. Social determinants of health equity. Am J Public Health. 2014;104(S4):S517–S519.
   PubMed Web of Science ®Google Scholar
• Marmot M, Friel S, Bell R, et al. Closing the gap in a generation: health equity through action on the social determinants of health. Lancet. 2008;372(9650):1661–1669.
   PubMed Web of Science ®Google Scholar
• Cameron A, Ewen M, Ball D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008;6736(8):1–22.
   Google Scholar
• Garcia MM, Barbosa MM, Silva RM, et al. Indicator of access to medicines in relation to the multiple dimensions of access. Comp Eff Res. 2019;8:1027–1039.
   Google Scholar
• BRASIL. 1988. Constituição federal de 1988. Brasília, DF: Diário Oficial da União. DOI:10.4304/jcp.6.9.1903-1912
   Google Scholar
• AGÊNCIA NACIONAL DE SAÚDE SUPLEMENTAR. 2017. Plano de Dados Abertos 2017-2019, 1–34. [cited 2019 Aug 21]. Available from: http://www.aneel.gov.br/documents/656835/15191504/DD_IG_1_10.pdf/f4abc8a9-a37a-d11f-5389-448470f77bae
   Google Scholar
• Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia : findings from the global burden of disease study. Schizophr Bull.2018;44(6):1195–1203.
   Google Scholar
• CHONG H, Teoh SL, Wu DB-C, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373.
   PubMed Web of Science ®Google Scholar
• Kirkbride JB, Fearon P, Morgan C, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes. Arch Gen Psychiatry. 2006;63(3):250.
   PubMed Web of Science ®Google Scholar
• Jongsma HE, Gayer-Anderson C, Lasalvia A, et al. Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiatry. 2018;75(1):36–46.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Sanon Aigbogun M, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 77(6): 2016. 2016.
   Web of Science ®Google Scholar
• Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7:1.
   Google Scholar
• Bloom DE, Cafiero ET, Jané-Llopis E, et al. The global economic burden of non-communicable diseases. Geneva: World Economic Forum; 2011. p. 910.
   Google Scholar
• BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. 2013. Portaria no 364, de 9 de abril de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas – esquizofrenia. Brasília, DF: Diário Oficial da União. 10.21542/gcsp.2016.29
   Google Scholar
• Barbosa WB, Costa JDO, Lovato L, et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics : an 11 ‑ year cohort in Brazil. Appl Health Econ Health Policy. 2018;16(5):697–709.
   PubMed Web of Science ®Google Scholar
• BRASIL. Ministério da Saúde. 1990. Lei no 8.080 (Lei Orgânica da Saúde), de 19 de setembro de 1990. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização dos serviços correspondentes, e dá outras providências. Brasília, DF: Diário Oficial da União.
   Google Scholar
• BRASIL. Ministério da Saúde. Conselho Nacional de Saúde. 2004. Resolução no 338, de 06 de maio de 2004. Aprova a Política Nacional de Assistência Farmacêutica. Brasília, DF: Diário Oficial da União.
   Google Scholar
• BRASIL. Ministério da Saúde. 2010. Da excepcionalidade às linhas de cuidado: o Componente Especializado da Assistência Farmacêutica.
   Google Scholar
• BRASIL. Ministério da Saúde. Gabinete do Ministro. 1998. Portaria no 3.916 de 30 de outubro de 1998 do Ministério da Saúde. Aprova a Política Nacional de Medicamentos. Brasília: Diário Oficial da União.
   Google Scholar
• Mullachery P, Silver D, Macinko J. Changes in health care inequity in Brazil between 2008 and 2013. Int J Equity Health. 2016;15:140; 1–12.
   PubMed Web of Science ®Google Scholar
• Da Silva MRR, Dos Santos JBR, Almeida AM, et al. Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: A post-incorporation analysis. J Comp Eff Res. 2018;7(10):989–1000.
   PubMed Web of Science ®Google Scholar
• De Araújo AA, De Araújo Dantas D, Do Nascimento GG, et al. Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. Psychiatr Q. 2014;85(3):357–367.
   PubMed Web of Science ®Google Scholar
• de Souza LA, Coutinho ESF. The quality of life of people with schizophrenia living in community in Rio de Janeiro, Brazil. Soc Psychiatry Psychiatr Epidemiol. 2006;41(5):347–356.
   PubMed Web of Science ®Google Scholar
• Brooks R, De Charro F. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
   PubMed Web of Science ®Google Scholar
• Santos M, Cintra MACT, Monteiro AL, et al. Brazilian valuation of EQ-5D-3L health states: results from a saturation study. Med Decis Mak. 2015;36(2):253–263.
   PubMed Web of Science ®Google Scholar
• de Almeida JL, Zuppo IDF, Castel S, et al. Health-related quality of life in patients treated with atypical antipsychotics. Rev Bras Psiquiatr (Sao Paulo, Brazil : 1999). 2020;1–9.
   PubMedGoogle Scholar
• Caqueo-Urízar A, Urzúa A, Boyer L, et al. Religion involvement and quality of life in patients with schizophrenia in Latin America. Soc Psychiatry Psychiatr Epidemiol. 2015;51(4):521–528.
   PubMed Web of Science ®Google Scholar
• Loch AA, Chianca C, Alves TM, et al. Poverty, low education, and the expression of psychotic-like experiences in the general population of São Paulo, Brazil. Psychiatry Res. 2017;253(August 2016):182–188.
   PubMedGoogle Scholar
• Neil AL, Carr VJ, Mackinnon A, et al. Health-related quality of life in people living with psychotic illness and factors associated with its variation. Value Health. 2018;21(8):1002–1009.
   PubMed Web of Science ®Google Scholar
• Thornicroft G, Ahuja S, Barber S, et al. Integrated care for people with long-term mental and physical health conditions in low-income and middle-income countries. Lancet Psychiatry. 2019;6(2):174–186.
   PubMed Web of Science ®Google Scholar
• Chekroud SR, Gueorguieva R, Zheutlin AB, et al. Association between physical exercise and mental health in 1·2 million individuals in the USA between 2011 and 2015: a cross-sectional study. Lancet Psychiatry. 2018;5(9):739–746.
   PubMed Web of Science ®Google Scholar
• IBGE. Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios - PNAD. IBGE. Vol. 39. Brasília, Brasil. ISSN 0101-4234; 2015.
   Google Scholar
• Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351–360.
   PubMed Web of Science ®Google Scholar
• Duvetorp A, Østergaard M, Skov L, et al. Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the nordic patient survey of psoriasis and psoriatic arthritis (NORPAPP). Arch Dermatol Res. 2019;311(5):351–360.
   PubMed Web of Science ®Google Scholar
• Gaite L, Vázquez-Barquero JL, Borra C, et al. Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand. 2002;105(4):283–292.
   PubMed Web of Science ®Google Scholar
• de Pinho G, Pereira LM, de Sousa Pereira AM, et al. Quality of life in schizophrenic patients: the influence of sociodemographic and clinical characteristics and satisfaction with social support. Trends Psychiatry Psychother. 2018;40(3):202–209.
   PubMedGoogle Scholar
• Mohr S, Perroud N, Gillieron C, et al. Spirituality and religiousness as predictive factors of outcome in schizophrenia and schizo-affective disorders. Psychiatry Res. 2011;186(2–3):177–182.
   PubMed Web of Science ®Google Scholar
• WHO. 2018. Guidelines for the management of physical health conditions in adults with severe mental disorders; [cited 2019 Aug 21]. Available from: http://apps.who.int/iris/bitstream/handle/10665/275718/9789241550383-eng.pdf
   Google Scholar
• Ward M, Druss B. Treatment considerations in severe mental illness caring for the whole patient. JAMA Psychiatry. 2019;76(7):759.
   PubMed Web of Science ®Google Scholar
• Druss B, Kern JS, Parks J, et al. Psychiatry’ s role in improving the physical health of patients with serious mental illness. Am Psychiatr Assoc. 2017;1–21.
   Google Scholar
• Siskind D, Mccartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;(February 2015):385–392. DOI:10.1192/bjp.bp.115.177261
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis. Lancet. 2014;951–962. DOI:10.1016/S0140-6736(13)60733-3.
   Google Scholar